SCHEMBL189043

SCHEMBL189043

C[N+](C)(C)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 5/20 0.39
GRIN3B O60391 5/20 0.39
GRIN1 Q05586 5/20 0.39
GRIN2A Q12879 5/20 0.39
GRIN2B Q13224 5/20 0.39
GRIN2C Q14957 5/20 0.39
GRIN3A Q8TCU5 5/20 0.39
LMNA P02545 2/20 0.38
SLC22A2 O15244 2/20 0.38
SLC47A1 Q96FL8 2/20 0.38
SLC22A1 O15245 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
STAT6 P42226 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483830 1.00 GRIN2D (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Bromide SCHEMBL2417281 0.97 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Fluoride Ion SCHEMBL1963198 0.97 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Water SCHEMBL30450574 0.97 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Water SCHEMBL190548 0.97 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL10324796 0.97 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Iodide SCHEMBL189260 0.97 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Water SCHEMBL28326185 0.94 GRIN2D (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Potassium Ion SCHEMBL28120587 0.94 GRIN2D (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Bicarbonate SCHEMBL2521298 0.87 THRB (0.39) THRBSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 722 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102760-A1 METHODS FOR PREPARING MOLECULAR SIEVES USING 1,1-DIETHYL-2,6-DIMETHYLPIPERIDIN-1-IUM AND MOLECULAR SIEVES PREPARED THEREFROM BASF MOBILE EMISSIONS CATALYSTS LLC (US) 2026-04-16 US claimed
US-20250382189-A1 ZEOLITE STRUCTURE SYNTHESIZED USING MIXTURES OF ORGANIC STRUCTURE DIRECTING AGENTS BASF MOBILE EMISSIONS CATALYSTS LLC (US) 2025-12-18 US claimed
US-12428305-B2 Zeolite structure synthesized using mixtures of organic structure directing agents BASF MOBILE EMISSIONS CATALYSTS LLC (US) 2025-09-30 US claimed
EP-4580992-A1 METHODS FOR PREPARING MOLECULAR SIEVES USING 1,1-DIETHYL-2,6-DIMETHYLPIPERIDIN-1-IUM AND MOLECULAR SIEVES PREPARED THEREFROM BASF Mobile Emissions Catalysts LLC (US) 2025-07-09 EP claimed
WO-2025133582-A1 A METHOD OF SYNTHESIZING A TITANATED ZEOLITE AND THE ZEOLITE OBTAINED THEREBY JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2025-06-26 WO claimed
US-20250205690-A1 A CHA TYPE ZEOLITE AND THE METHOD OF SYNTHESISING SAID ZEOLITE JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2025-06-26 US claimed
CN-120035566-A Method for preparing molecular sieve using 1, 1-diethyl-2, 6-dimethylpiperidin-1-ium and molecular sieve prepared therefrom 巴斯夫移动排放催化剂有限公司 2025-05-23 CN claimed
CN-119998234-A Enhanced hydrothermal stability of zeolites for selective catalytic reduction applications 巴斯夫移动排放催化剂有限公司 2025-05-13 CN claimed
EP-4526253-A1 A CHA TYPE ZEOLITE AND THE METHOD OF SYNTHESISING SAID ZEOLITE Johnson Matthey Public Limited Company (GB) 2025-03-26 EP claimed
WO-2025024640-A2 METHOD FOR MAKING CHA ZEOLITES AND ZEOTYPES PURDUE RESEARCH FOUNDATION (US) 2025-01-30 WO claimed
EP-1701914-A2 CHABAZITE-CONTAINING MOLECULAR SIEVE, ITS SYNTHESIS AND ITS USE IN THE CONVERSION OF OXYGENATES TO OLEFINS ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) 2006-09-20 EP claimed
US-7094389-B2 Chabazite-containing molecular sieve, its synthesis and its use in the conversion of oxygenates to olefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-08-22 US claimed
US-20050197520-A1 Chabazite-type molecular sieve, its synthesis and its use in the conversion of oxygenates to olefins SYMYX SOLUTIONS, INC. 2005-09-08 US claimed
WO-2005063623-A2 CHABAZITE-CONTAINING MOLECULAR SIEVE, ITS SYNTHESIS AND ITS USE IN THE CONVERSION OF OXYGENATES TO OLEFINS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-07-14 WO claimed
WO-2005063622-A2 CHABAZITE-TYPE MOLECULAR SIEVE, ITS SYNTHESIS AND ITS USE IN THE CONVERSION OF OXYGENATES TO OLEFINS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-07-14 WO claimed
US-20050154244-A1 Chabazite-containing molecular sieve, its synthesis and its use in the conversion of oxygenates to olefins SYMYX SOLUTIONS, INC. 2005-07-14 US claimed
EP-0566680-B1 LAYERED OXIDE MATERIALS AND SWOLLEN AND PILLARED FORMS THEREOF MOBIL OIL CORP (US) 1998-04-29 EP claimed
US-5516962-A Catalyst and process for isoparaffin-olefin alkylation MOBIL OIL CORP. (US) 1996-05-14 US claimed
US-5354718-A Catalyst and process for isoparaffin-olefin alkylation MOBIL OIL CORPORATION (US) 1994-10-11 US claimed
EP-0139504-B1 ADAMANTYLAMINE/LONG CHAIN ALKYLAMINE CATALYSTS AND USE IN PARAFFIN-OLEFIN ALKYLATION PROCESS EXXON RESEARCH AND ENGINEERING COMPANY (US) 1988-06-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102760-A1 METHODS FOR PREPARING MOLECULAR SIEVES USING 1,1-DIETHYL-2,6-DIMETHYLPIPERIDIN-1-IUM AND MOLECULAR SIEVES PREPARED THEREFROM HNRNPM, UFM1, B2M GRIN2D 2686/4885GRIN3B 3509/4885GRIN1 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.